LifeMD (LFMD) Stock Forecast & Price Target

LifeMD Inc. has demonstrated significant growth, with its Telehealth active subscriber base increasing by 27% year-over-year to 275,267 by the end of 2024, and Telehealth revenue rising 60% year-over-year to $49.9 million. The growth in Telehealth revenue indicates a concurrent rise in average revenue per subscriber, further supported by an increase in Zepbound approval due to a recent partnership, highlighting the potential for future revenue growth. Additionally, the company's strategic move into networks for commercial and Medicare is projected to significantly enhance revenue contribution over the next few years, reinforcing a positive outlook for overall growth in 2025 and beyond.

LifeMD faces significant risks that contribute to a negative outlook on its stock, including the potential for lower-than-projected growth in telehealth revenue and challenges in acquiring and retaining new patients. The company's financials also indicate a net loss of $22 million, translating to a loss of $0.53 per share, coupled with conservative revenue guidance that anticipates a drastic reduction in compounded medication revenue. Furthermore, competition in the telehealth and lifestyle markets is expected to intensify, particularly from large, established players, which may hinder LifeMD's ability to achieve profitability and maintain its market position.